Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 33320214.
- Also identified by DOI 10.1001/jama.2020.21512 and PMC identifier PMC7456454.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study uses commercial and Medicare Advantage claims data to compare medication fills, outpatient visits, and urine tests for opioid use disorder in January-May 2020 vs 2019.